A review of hundreds of cases finds that only a minority of patients noted being sick with a coronavirus infection prior to developing the severe inflammatory condition.
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
Never miss an email from The Scientist. Click hereto add The Scientist to your safe-sender list.
The Scientist,1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801 Toll-Free: (888) 781-0328 | Phone: (705) 528-6888 Email: privacy@labxmediagroup.com